- Company
- ‘Leclaza combo extends survival without chemotherapy’
- by Son, Hyung Min Oct 15, 2025 11:37am
- “The MARIPOSA study is the first clinical trial to significantly extend overall survival using two targeted therapies without chemotherapy. Discussions on EGFR-mutated lung cancer treatment will now shift to focus on overall survival.” During a recent interview with Dailypharm, Professors Byoung Chul Cho and Sun Min Lim of Yonsei Cancer
- Company
- Will the MM drug Elrexfio be reimbursed this time?
- by Eo, Yun-Ho Oct 15, 2025 06:12am
- Whether progress will be made for the new multiple myeloma drug Elrexfio (elranatamab) in its second attempt to secure reimbursement in Korea is gathering attention. According to industry sources, Pfizer Korea's bispecific antibody therapy Elrexfio (elranatamab) is expected to be submitted for reimbursement review to the Health Insurance
- Opinion
- [Op-Ed] Patients, no time left for 'new drug comb therapies'
- by Eo, Yun-Ho Oct 15, 2025 06:11am
- "My father (in his 60s), who has been diagnosed with urothelial carcinoma, is paying 10 million won every three weeks for combination cancer therapy that is non-reimbursed. The disaster medical expense program provided the cost. However, we feel helpless upon the news that the fund is being delayed." This is part of a public complaint file
- Policy
- New Divisions for Essential & Public Healthcare proposed
- by Lee, Jeong-Hwan Oct 15, 2025 06:11am
- The Ministry of Health and Welfare has decided to establish a new director-level organization, the ‘Regional, Essential, and Public Healthcare Policy Office,’ to ensure the success of the Lee Jae-myung administration's national policy task of people-focused healthcare reform. It has been confirmed that this request has been submitted to th
- Company
- GSK’s myelofibrosis drug Omjjara faces reimb hurdles
- by Eo, Yun-Ho Oct 14, 2025 06:41am
- The reimbursment of GSK’s new myelofibrosis drug Omjjara has become uncertain in Korea. According to Dailypharm coverage, the reimbursement application for GSK Korea's myelofibrosis treatment Omjjara (momelotinib), which had passed the Cancer Disease Deliberation Committee of the Health Insurance Review and Assessment Service (HIRA) in M
- Company
- Hugel appoints Carrie Strom as global CEO
- by Chon, Seung-Hyun Oct 14, 2025 06:41am
- Hugel announced on October 13 that it has appointed Carrie Strom, a medical aesthetics leader and a former Senior Vice President at AbbVie, as its new Global CEO. Carrie Strom will lead Hugel's global business operations. She is highly regarded as an expert in the aesthetics field, having served for five years, from May 2020 to February th
- Product
- KMA forms special committee to block INN prescribing
- by Kang, Shin-Kook Oct 14, 2025 06:41am
- The Korean Medical Association (KMA) has formed a special countermeasure committee to block the institutionalization of international non-proprietary name (INN) prescribing. This is seen as a response to demands by some delegates for an extraordinary general meeting. KMA (President Taek-woo Kim) said on the 13th, “Policies such as INN pr
- Company
- Entresto patent dispute near its end, yet 0 generic approval
- by Kim, Jin-Gu Oct 14, 2025 06:40am
- The patent dispute of Novartis' heart failure treatment, 'Entresto,' is nearing its final judgment. Still, generic companies may be unable to launch their products early, regardless of the ruling. To launch a generic early, companies need not only to win the patent dispute but also to secure product approval from the Ministry of Food and
- Opinion
- [Desk’s View] Lift botulinum toxin’s core tech designation
- by Lee, Seok-Jun Oct 14, 2025 06:40am
- Calls to lift the “national core technology” designation from botulinum toxin are rising once again &8212; and this time, the long-standing issue must be resolved. The industry has been calling for this for a long time. The demand was made in 2023, and again the following year. Yet, it remains stuck in neutral. The decision must now b
- Policy
- Gov't to unveil New drugs·Generic Drug Pricing System Rev.
- by Lee, Jeong-Hwan Oct 14, 2025 06:40am
- The Ministry of Health and Welfare (MOHW) has announced plans to release the drug pricing system revision next month (November), including both new drugs and generics. It is drawing the attention of Korean and international pharmaceutical companies. The MOHW plans to disclose the timing of the re-evaluation of reimbursement appropriatene
